World Journal of Urology

, Volume 36, Issue 2, pp 257–263 | Cite as

Renal function recovery after radical nephroureterectomy for upper tract urothelial carcinoma

  • Byron H. Lee
  • Emily C. Zabor
  • Daniel Tennenbaum
  • Helena Furberg
  • Nicole Benfante
  • Jonathan A. Coleman
  • Edgar A. Jaimes
  • Paul RussoEmail author
Original Article



To understand the longitudinal renal function trends in patients undergoing radical nephroureterectomy (RNU) and identify clinicopathologic characteristics associated with estimated glomerular filtration rate (eGFR) recovery.


147 patients were available for analysis. Longitudinal eGFR trends were assessed by plotting each patient’s eGFR measurements over time. The patient population was dichotomized using eGFR < 60 ml/min/1.73 m2 versus ≥ 60 ml/min/1.73 m2. Cumulative incidence and competing risk regression analysis were used to estimate recovery of postoperative eGFR to the preoperative level and identify clinicopathologic characteristics associated with eGFR recovery.


Median age was 68.7 years and median preoperative eGFR was 55.9 ml/min/1.73 m2. 63.6% were male and 95.8% were white. The cumulative incidence of eGFR recovery was significantly higher in patients with baseline eGFR < 60 ml/min/1.73 m2 compared to those with baseline eGFR ≥ 60 ml/min/1.73 m2 (p = 0.01), with recovery rates at 2 years of 56.6% vs. 27.7%, respectively. Multivariable analysis revealed that preoperative hydronephrosis (HR 1.80) and preoperative eGFR < 60 ml/min/1.73 m2 (HR 1.87) were associated with increased chance of eGFR recovery.


Over half of patients with preoperative eGFR < 60 ml/min/1.73 m2 achieved eGFR recovery within the first 3 years after RNU, and hydronephrosis was a significant predictor of recovery. These findings should be considered when counseling patients regarding chronic kidney disease progression after RNU and timing of perioperative chemotherapy for high risk tumors.


Upper tract urothelial carcinoma Renal function recovery Radical nephroureterectomy Hydronephrosis 


  1. 1.
    Munoz JJ, Ellison LM (2000) Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol 164(5):1523–1525CrossRefPubMedGoogle Scholar
  2. 2.
    Siegel RL, Miller KD, Jemal A (2017) Cancer Statistics. CA Cancer J Clin 67(1):7–30. CrossRefPubMedGoogle Scholar
  3. 3.
    Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Kurella Tamura M, Feldman HI (2014) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 63(5):713–735. CrossRefPubMedGoogle Scholar
  4. 4.
    Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Bohle A, Van Rhijn BW, Kaasinen E, Palou J, Shariat SF (2015) European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol 68(5):868–879. CrossRefPubMedGoogle Scholar
  5. 5.
    Network NCC Bladder Cancer Version 1.2017—December 21, 2016. Accessed Jan 16, 2017
  6. 6.
    Simhan J, Smaldone MC, Egleston BL, Canter D, Sterious SN, Corcoran AT, Ginzburg S, Uzzo RG, Kutikov A (2014) Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma. BJU Int 114(2):216–220. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Seisen T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, Yuan CY, Babjuk M, Bohle A, Burger M, Comperat EM, Cowan NC, Kaasinen E, Palou J, van Rhijn BW, Sylvester RJ, Zigeuner R, Shariat SF, Roupret M (2016) Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU non-muscle invasive bladder cancer guidelines panel. Eur Urol 70(6):1052–1068. CrossRefPubMedGoogle Scholar
  8. 8.
    Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J (2014) A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 66(3):529–541. CrossRefPubMedGoogle Scholar
  9. 9.
    Kaag MG, O’Malley RL, O’Malley P, Godoy G, Chen M, Smaldone MC, Hrebinko RL, Raman JD, Bochner B, Dalbagni G, Stifelman MD, Taneja SS, Huang WC (2010) Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 58(4):581–587. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hoshino K, Kikuchi E, Tanaka N, Akita H, Ito Y, Miyajima A, Jinzaki M, Oya M (2012) Preoperative hydronephrosis: independent predictor for changes in renal function following nephroureterectomy. Jpn J Clin Oncol 42(3):202–207. CrossRefPubMedGoogle Scholar
  11. 11.
    Kaag M, Trost L, Thompson RH, Favaretto R, Elliott V, Shariat SF, Maschino A, Vertosick E, Raman JD, Dalbagni G (2014) Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma. BJU Int 114(5):674–679. CrossRefPubMedGoogle Scholar
  12. 12.
    Raman JD, Lin YK, Kaag M, Atkinson T, Crispen P, Wille M, Smith N, Hockenberry M, Guzzo T, Peyronnet B, Bensalah K, Simhan J, Kutikov A, Cha E, Herman M, Scherr D, Shariat SF, Boorjian SA (2014) High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. Urol Oncol 32(1):47 e49-14. CrossRefGoogle Scholar
  13. 13.
    Rodriguez Faba O, Palou J, Breda A, Maroto P, Fernandez Gomez JM, Wong A, Villavicencio H (2014) Predictive factors for impaired renal function following nephroureterectomy in upper urinary tract urothelial cell carcinoma. Urol Int 92(2):169–173. CrossRefPubMedGoogle Scholar
  14. 14.
    Hashimoto T, Ohno Y, Nakashima J, Gondo T, Nakagami Y, Namiki K, Horiguchi Y, Yoshioka K, Ohori M, Tachibana M (2015) Prediction of renal function after nephroureterectomy in patients with upper tract urothelial carcinoma. Jpn J Clin Oncol 45(11):1064–1068. CrossRefPubMedGoogle Scholar
  15. 15.
    Singla N, Gayed BA, Bagrodia A, Krabbe LM, Palazzi KL, Mirheydar H, Harrow B, Jacobs C, Youssef R, Darwish O, Sagalowsky A, Lotan Y, Derweesh I, Margulis V (2015) Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma. Urol Oncol 33(6):268 e261–267. CrossRefGoogle Scholar
  16. 16.
    Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ckd EPI (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Zabor EC, Furberg H, Mashni J, Lee B, Jaimes EA, Russo P (2016) Factors associated with recovery of renal function following radical nephrectomy for kidney neoplasms. Clin J Am Soc Nephrol 11(1):101–107. CrossRefPubMedGoogle Scholar
  18. 18.
    Lai MN, Wang SM, Chen PC, Chen YY, Wang JD (2010) Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 102(3):179–186. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Matin SF, Margulis V, Kamat A, Wood CG, Grossman HB, Brown GA, Dinney CP, Millikan R, Siefker-Radtke AO (2010) Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116(13):3127–3134. CrossRefPubMedGoogle Scholar
  20. 20.
    Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF (2014) Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 120(12):1794–1799. CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Aziz A, Dobruch J, Hendricksen K, Kluth LA, Necchi A, Noon A, Rink M, Roghmann F, Seiler R, Gontero P, Kassouf W, Shariat SF, Xylinas E, Young Academic Urologists Urothelial Carcinoma Group of the European Association of U (2017) Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. World J Urol. Google Scholar
  22. 22.
    Seisen T, Krasnow RE, Bellmunt J, Rouprêt M, Leow JJ, Lipsitz SR, Vetterlein MW, Preston MA, Hanna N, Kibel AS, Sun M (2017) Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma. J Clin Oncology 35(8):852–860CrossRefGoogle Scholar
  23. 23.
    Lane BR, Smith AK, Larson BT, Gong MC, Campbell SC, Raghavan D, Dreicer R, Hansel DE, Stephenson AJ (2010) Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer 116(12):2967–2973. CrossRefPubMedGoogle Scholar
  24. 24.
    Xylinas E, Rink M, Margulis V, Clozel T, Lee RK, Comploj E, Novara G, Raman JD, Lotan Y, Weizer A, Roupret M, Pycha A, Scherr DS, Seitz C, Ficarra V, Trinh QD, Karakiewicz PI, Montorsi F, Zerbib M, Shariat SF, Collaboration U (2013) Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU Int 112(4):453–461. CrossRefPubMedGoogle Scholar
  25. 25.
    Singla N, Hutchinson R, Haddad A, Sagalowsky A, Lotan Y, Margulis V (2016) Preoperative hydronephrosis is associated with less decline in renal function after radical nephroureterectomy for upper tract urothelial carcinoma. Can J Urol 23(4):8334–8341PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  • Byron H. Lee
    • 1
  • Emily C. Zabor
    • 2
  • Daniel Tennenbaum
    • 1
  • Helena Furberg
    • 2
  • Nicole Benfante
    • 1
  • Jonathan A. Coleman
    • 1
  • Edgar A. Jaimes
    • 3
  • Paul Russo
    • 1
    Email author
  1. 1.Department of Surgery, Urology ServiceMemorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.Department of Epidemiology and BiostatisticsMemorial Sloan Kettering Cancer CenterNew YorkUSA
  3. 3.Department of MedicineRenal Service at Memorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations